Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m? is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
October 11, 2022
Assignees:
GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
October 11, 2022
Assignees:
East China University Of Science And Technology, Yunnan University, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
September 27, 2022
Inventors:
Louise Kristine Vigsnæs, Bruce McConnell
Abstract: The present specification discloses a composition for preventing or improving intrinsic aging comprising, as an active ingredient, any one of paeoniflorin or a salt, isomer, hydrate or solvate thereof; and albiflorin or a salt, isomer, hydrate or solvate thereof. Intrinsic aging is one of the natural phenomena occurring with aging, unlike photoaging caused by UV, which is a type of extrinsic aging. The paeoniflorin or albiflorin of the present disclosure is useful for those who want to delay aging and maintain beauty. Accordingly, the paeoniflorin or a salt, isomer, hydrate or solvate thereof; and the albiflorin or a salt, isomer, hydrate or solvate thereof of the present disclosure have the advantage of being capable of being utilized in various forms such as cosmetics, functional health foods, etc.
Type:
Grant
Filed:
November 22, 2018
Date of Patent:
September 20, 2022
Assignee:
Amorepacific Corporation
Inventors:
Jin Sup Shim, Eun Jung Lee, Nok Hyun Park, Yong Jin Kim
Abstract: A pharmaceutical composition for treating viral infections, including treatments for treatments for coronavirus infections, such as SARS-CoV-2 infections, and illnesses due to the viral infections, such as COVID-19 is provided herein. Also provided are methods for treating viral infections as well as illnesses due to viral infections, such as COVID-19.
Type:
Grant
Filed:
December 30, 2021
Date of Patent:
September 20, 2022
Assignee:
Feynman Labs, LLC
Inventors:
Carl Johan Freer, Richard Kaszynski, Alessandro Gadotti
Abstract: The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.
Abstract: The present invention relates to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract as an active ingredient, and more particularly, to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract having effects of regenerating the Bruch's membrane of an eye and improving a transport function. The composition according to the present invention improves the transport function of the Bruch's membrane and promotes the regeneration of the Bruch's membrane, thereby delaying or reversing an eye aging process, and thus has excellent effects on the prevention and treatment of a disease such as age-related macular degeneration (AMD), Sorsby's fundus dystrophy, Malattia Levintanese (ML), Stargardt disease, Best's vitelliform retinal dystrophy and Doyne's honeycomb retinal dystrophy (DHRD), which occurs due to the age-related dysfunction of the Bruch's membrane.
Abstract: The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
August 16, 2022
Assignee:
Korea University Research and Business Foundation
Inventors:
Kyoung Heon Kim, Jungwoo Yang, Ju Hwan Song, Sora Yu
Abstract: The antioxidant compositions of various embodiments comprise methyl carboxymethylphenylaminocarboxy propylphosphonate, also known as MCAP, (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid, also known as rosmarinic acid, and 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[?-L-rhamnopyranosyl-(1?6)-?-D-glucopyranosyloxy]-4H-chromen-4-one, also known as rutin wherein the antioxidant composition demonstrate a synergistic effect compared with the MCAP, the rosmarinic acid, or the rutin alone. The methods include treating skin or hair damaged by reactive oxygen species, preventing skin or hair damage, and treating aged skin.
Type:
Grant
Filed:
January 15, 2021
Date of Patent:
August 2, 2022
Assignee:
Rodan & Fields, LLC
Inventors:
Olga Dueva-Koganov, Taylor Oswald, Christine Crane, Robert Bianchini
Abstract: A subject of the invention is a cosmetic composition comprising: —from 30% to 89% by weight of at least one polar oil relative to the total weight of the composition; —from 10% to 45% by weight of at least one C2-C6 aliphatic monoalcohol relative to the total weight of the composition; —from 0.5% to 50% by weight of at least one polyol relative to the total weight of the composition; —at least one hydrophilic active agent, said composition comprising less than 7% by weight of water relative to the total weight of the composition. It also relates to the associated cosmetic process and also the cosmetic use of said composition.
Abstract: A method of producing an injectable gel product is provided, comprising (a) cross-linking a first glycosaminoglycan (GAG) with a first crosslinking agent to produce a gel, wherein the charging ratio of crosslinking agent to disaccharide unit is below 0.15; (b) preparing particles of the gel; (c) mixing the glycosaminoglycan (GAG) gel particles with a second GAG to provide a mixture; (d) cross-linking the mixture with a second crosslinking agent to obtain cross-linking between the GAGs of the second, outer phase, thereby providing a gel having a first, inner phase of the cross-linked GAG gel particles, embedded in a gel of the second GAG outer phase; and (e) preparing injectable particles, each such particle containing a plurality of the cross-linked GAG gel particles of the first, inner phase. An injectable gel product, an aqueous composition, and a pre-filled syringe as also provided.
Abstract: The present invention relates to a method of removing residual organic solvent from crystalline oligosaccharides by the use of water vapour as well as the pharmaceutically and nutritionally suitable crystalline oligosaccharides obtained by said method.
Type:
Grant
Filed:
October 31, 2017
Date of Patent:
July 12, 2022
Assignee:
GLYCOM A/S
Inventors:
Pierre Chassagne, Martin Matwiejuk, Nikolay Khanzhin, Markus Jondelius Hederos
Abstract: A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.
Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.
Type:
Grant
Filed:
July 17, 2018
Date of Patent:
July 5, 2022
Inventors:
Amirreza Faridmoayer, Rainer Follador, Stefan Jochen Kemmler, Michael Thomas Kowarik, Gerald Johann Posch, Fabio Serventi
Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the to compositions also comprise a borate compound.
Type:
Grant
Filed:
October 1, 2020
Date of Patent:
July 5, 2022
Assignee:
Alcon Inc.
Inventors:
James W. Davis, Howard Allen Ketelson, Elaine E. Campbell, David L. Meadows, Rekha Rangarajan
Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.
Abstract: Disclosed are pharmaceutical compositions in gel form comprising a hydrophilic matrix consisting of a hyaluronic acid derivative containing an amide local anaesthetic in base form.
Type:
Grant
Filed:
January 23, 2019
Date of Patent:
June 14, 2022
Assignee:
FIDIA FARMACEUTICI S.p.A.
Inventors:
Andrea Pastorello, Fabio Bettella, Devis Galesso
Abstract: The present invention provides a composition for preventing or mitigating dementia in a subject comprising a mixture of tocotrienols, tocopherol, squalene and B vitamin, and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
August 17, 2016
Date of Patent:
June 14, 2022
Assignee:
Attest Research Sdn Bhd
Inventors:
Kah Hay Yuen, David Sue San Ho, Jia Woei Wong
Abstract: The present invention concerns compositions for rinsing the nasal cavity and the sinus cavities for curative or prophylactic treatments of acute and/or chronic rhinitis, and acute and/or chronic sinusitis, comprising: sodium chloride and/or potassium chloride; quercetin, and at least one active agent of the polyphenolic group chosen from the compounds: quercetin-4?-glycoside, 2-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxy-3(2H)-benzofuranone, protocatechuic acid; and wherein the quercetin is in the anhydrous form with an approximate molecular mass of 302 g/mol, or in the form of quercetin hydrate with an approximate molecular mass of 320 g/mol, or in the form of quercetin dihydrate with an approximate molecular mass of 338 g/mol. The present invention also relates to the methods for preparing these compositions and the method for treating acute and chronic rhinosinusitis using these compositions.